ERRATUM

PRL-3 siRNA Inhibits the Metastasis of B16-BL6 Mouse Melanoma Cells In Vitro and In Vivo

Feng Qian, Yu-Pei Li, Xia Sheng, Zi-Chao Zhang, Ran Song, Wei Dong, Shao-Xian Cao, Zi-Chun Hua, Qiang Xu

Figure 5 for this article was incorrectly presented in a recent issue ( 13[3–4], March–April 2007). A revised image appears to the right.

Figure 5.

Effect of PRL-3 siRNA on the spontaneous metastasis of B16-BL6 melanoma cells in vivo. B16-BL6 cells (20 μL, 2.5 × 10⁶ cells/mL) were injected subcutaneously into right footpads of C57BL/6J mice (100% of injected mice formed tumors). Ten days after injection, the mice were distributed into four groups according to tumor size. The tumors were injected with PBS, Luc siRNA, and PRL-3 siRNA (3 or 6 μg) four times every 4 days. (A) After 26 days, mice were killed, and the footpads inoculated with B16-BL6 cells were resected. (B) Time course of tumor growth. Tumor volumes were measured every 4 days from day 10 to 26 after inoculation. Data are mean ± SEM of five mice in each group. A significant difference was shown compared with the PBS control group. *P < 0.05 vs. Luc siRNA control. (C) Draining popliteal lymph node from injected footpads. The arrow indicates the spontaneous metastatic B16-BL6 tumor. (D) Survival curve of mice (n = 10) treated with PBS, Luc-siRNA, or PRL-3 siRNA (3 or 6 μg). Results were evaluated by the Kaplan-Meier method. The differences between the Luc-siRNA control group and the two treatment groups are statistically significant, *P < 0.01.